Company News

December 11, 2015 - 60P has received the first tranche of $4 million in a debt financing deal with Knight Therapeutics Inc., in support of our drug development program for tropical diseases.

August 31, 2015 - 60P has received approval to conduct a clinical study with celgosivir and modipafant in dengue patients in collaboration with Singapore General Hospital.

May 1, 2015 - 60P was recently invited to present at the Cavendish Global Forum in La Jolla, California, on May 11-14, 2015.

April 28, 2015 
- 60P recently entered into a cooperative research and development agreement with the United States Army to commercialize 60P003 (INN name is tafenoquine) for malaria prophylaxis.

July 30, 2014 - 60P recently entered into an exclusive licensing deal with SingHealth and Duke-National University of Singapore Graduate Medical School to further develop celgosivir (60P001) for dengue fever. 60P is preparing to conduct a Phase II clinical trial beginning in the second half of 2015.

June 11, 2014
 - Recently, one of 60P's partners, Duke-NUS Medical School and its collaborators, completed a phase I clinical study that demonstrated the safety of celgosivir in dengue patients and a trend towards faster NS1 clearance, suggesting the possibility of mitigating vascular permeability syndrome using glucosidase inhibitors.

April 1 2014 - 60P has entered into a research collaboration agreement with the Duke-NUS Medical School, to investigate the utility of different combinations of dengue drugs, including in vitro and in animal models. Dengue, like other viral diseases such as hepatitis C and HIV, will likely require a combination of different host and virus-targeted molecules to achieve useful clinical benefit. The studies will be performed in the laboratory of Dr. Subhash Vasudevan.

January 1, 2014
 - 60P recently established a subsidiary, 60P Australia, Pty. Ltd. 60P Australia will take the lead in continuing the company's development of dengue therapeutics.

April 9, 2013 
- A recent report suggests that the incidence of dengue may have been under-estimated by a factor of three. Therefore, prior estimates, including our own, of economic burden and the potential market for dengue drugs, will need to be revised upwards.

September 8, 2012 - 60P has published the first description of the potential market for dengue drugs in Antiviral Research (Dow and Mora, 2012, Antiviral Research 96:203-212). Based on publicly available information regarding the medical costs and lost productivity associated with clinical cases of dengue, we estimate that annual economic burden of dengue is at least $1.7 billion. Assuming that the economic burden relieved by future dengue drugs was shared between national governments and manufacturers, we estimate that the potential market for dengue drugs is $338 million annually.

About  |  Tropical Diseases  |  Products  |  Research  |  Responsibility  |  Investors  |  Media  |  Careers  |  Contact 

 1025 Connecticut Avenue NW, Suite 1000   Washington DC 20036 
Phone: 1-240-351-1167   Email: 

 Content © 2017. 60° Pharmaceuticals, LLC. All rights reserved.